Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

de Graan, Anne-Joy M;Lancaster, Cynthia S;Obaidat, Amanda;Hagenbuch, Bruno;Sparreboom, Alex;et.al.
(2012) Clinical Cancer Research — Vol. 18, n° 16, p. 4433-4440 (2012)

Files

DEGRAANInfluenceofpolymorphicOATP1BClinCancerRes2012.pdf
  • Restricted Access
  • Adobe PDF
  • 973.6 KB
Request a copy

Details

Authors
  • de Graan, Anne-Joy M
    Author
  • Lancaster, Cynthia S
    Author
  • Obaidat, Amanda
    Author
  • Hagenbuch, Bruno
    Author
  • Sparreboom, Alex
    Author
Show more
Abstract
The existence of at least two potentially redundant uptake transporters in the human liver with similar affinity for docetaxel supports the possibility that functional defects in both of these proteins may be required to confer substantially altered disposition phenotypes. In view of the established exposure-toxicity relationships for docetaxel, we suggest that caution is warranted if docetaxel has to be administered together with agents that potently inhibit both OATP1B1 and OATP1B3.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

de Graan, A.-J. M., Lancaster, C. S., Obaidat, A., Hagenbuch, B., Elens, L., Friberg, L. E., de Bruijn, P., Hu, S., Gibson, A. A., Bruun, G. H., Corydon, T. J., Mikkelsen, T. S., Walker, A. L., Du, G., Loos, W. J., van Schaik, R. H. N., Baker, S. D., Mathijssen, R. H. J., & Sparreboom, A. (2012). Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clinical Cancer Research, 18(16), 4433-4440. https://doi.org/10.1158/1078-0432.CCR-12-0761 (Original work published 2012)